

Express Mail Label No. EV 337 197 264 US

Attorney Docket No. 59150-8033

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: LEE et al.

APPLICATION NO.: NOT YET ASSIGNED

INTL. FILING DATE: 26 JUNE 2003

PRIORITY DATE: 02 JULY 2002

FOR: AGARICUS EXTRACT FOR PREVENTING THE

INDUCTION OR METASTASIS OF CANCER

EXAMINER: NOT YET ASSIGNED

ART UNIT: NOT YET ASSIGNED

CONF. NO.: NOT YET ASSIGNED

<u>Information Disclosure Statement Within Three Months of</u> <u>Application Filing or Before First Action – 37 CFR 1.97(b)</u>

Mail Stop PCT
Attn: DO/EO/US
Commissioner for Patents
P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2.	Cited	Information

\boxtimes	Copies	of the following references are enclosed:
	\boxtimes	All cited references
		References marked by asterisks
		The following:
	Copies	of the following references can be found in parent Application No.
		All cited references
		References marked by asterisks
		The following:

The following references are not in English. For each such reference, the undersigned has enclosed (i) a translation of the reference; (ii) a copy of a communication from a foreign patent office or International Searching



Express Mail Label No. EV 337 197 264 US

Attorney Docket No. 59150-8033

Authority citing the reference, (iii) a copy of a reference which appears to be an
English-language counterpart, or (iv) an English-language abstract for the
reference prepared by a third party. Applicant has not verified that the
translation, English-language counterpart or third-party abstract is an accurate
representation of the teachings of the non-English reference, though, and
reserves the right to demonstrate otherwise.

☐ All cited references
 ☑ References marked by an asterisk
 ☐ The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 CFR 1.704(d))

□ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,

Date: <u>Neumber 30, 2004</u>

Correspondence Address: Customer No. 22918 Phone: 650 838-4300 Judy M. Mohr

Registration No.38,563

10/519971 ec'd PCT/PT0 30 DEC 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

Sheet 1 of 1

D112.00						
COMPLETE IF KNOWN						
Application Number	not yet assigned					
Filed	December 30, 2004					
First Named Inventor	LEE					
Group Art Unit	not yet assigned					
Examiner Name	not yet assigned					
Atty Dkt No.	59150-8033					
Title:	Agaricus Extract for Preventing the					

U.S. PATENT DOCUMENTS											
Examiner Initials	Cite	e			or	Date of Publication or Filing Date of Cited Document		Pages, Columns, Lines, Where Relevant Figures Appear			
			F	OR	EIGN PATENT DOCUMEN	TS					
Examiner	Cite	Fore	ign Patent or Application	1	Name of Patentee or Applicant	Date of		Col Lines	ages, lumns, s, Where		
Initial	No.	Office	NUMBER (if kno		of Cited Document		Document		elevant		T
	*	JP	11 113531		Takuichi <i>et al.</i>	04/27/	04/27/99			Abs Onl	tract y
	*	JP	2003-128561		Nobuo, Yamaguchi	05/08/	/03			Abs Only	tract y
	*	JP	2000-038347		Toshimitsu et al.	02/08/	02/08/00			Abstract Only	
	*	JP	2001-010970		Tomihisa et al.	01/16/	/01			Abs Only	stract y
	*	JP	07-258107		Hitoshi et al.	10/09/95				Abstract Only	
	*	JP	2002-145796		Katsuhiko, Hayashi	05/22/02			_	Abstract Only	
	*	JP	2002-308777		Hiromichi et al.	10/23/02				Abstract Only	
OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS											
Examiner Initials	-						Т				
	*	Kadosawa, T. et al., "Clinical Efficacy of Agaricus Blazei Murill and/or Shark Cartilage in Dogs and Cats with Tumors", Jpn. J. Small Anim. Pract., 20 (2):101-109, 2001.					No				
		Copy of International Search Report (ISR) dated 08/19/03 from PCT/JP03/008157.									

EXAMINER		DATE CONSIDERED						
		DATE CONCIDENCE						
1								
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in							
	conformance and not considered. Include copy of this form with next communication to application(s).							
ı								